Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy - Experience in an Asian population

Annals of the Academy of Medicine Singapore

Volumn 27, Issue 5, 1998, Pages 645-649

  Tay, S K ^a   Thilagam, M D ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NONE

Author keywords

Cyto reductive surgery; Gynaecologic malignancies; Neuropathy; Neutropenia; Tumour response

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; NEUTROPENIA; OVARIECTOMY; OVARY CANCER;

EID: 0032445632     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Petterson F. Annual report on the results of treatment in gynaecologic cancer (volume 21). Int J Obstet Gynecol 1991; 36:238-57.
2. Tay S K, Chang T C. An evaluation of the policy of routine treatment of advanced epithelial ovarian carcinoma by debulking surgery and combined platinum-cyclophosphamide chemotherapy in Singapore. Int J Gynecol Cancer 1996; 6:44-8.
3. Schwartz P E, Smith J P. Surgical management of ovarian cancer. Arch Surg 1981; 116:99-106.
4. Ozols R F. Chemotherapy for advanced epithelial ovarian cancer. Hematol Oncol Clin North Am 1992; 6:879-94.
5. Advanced Ovarian Cancer Trialist Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 1991; 303:884-93.
6. Ozols R F. Advances in the chemotherapy of gynaecologic malignancies. Haematol Oncol 1992; 10:43-51.
7. Markman M, Rothman R, Hakes T. Second line cisplatin treatment in patients with ovarian cancer previously treated with cisplatin. Proc Am Soc Clin Oncol 1990; 9:599.
8. McGuire W P, Rowinsky E K, Rosenhein N B, Grumbine F C, Ettinger D S, Armstrong D K, et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111:273-9.
9. Kohn E C, Sarosy G, Bicher A, Link C, Christian M, Steinberg S M, et al. Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86:18-24.
10. Einzig A I, Wiernik P H, Sasloff J, Runowicz C D, Goldberg G L. Phase II study and long term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. Clin Oncol 1992; 10:1748-53.
11. Thigpen J T, Blessing J, Ball H, Hummel S J, Barrett R J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynaecologic Oncology Group study. J Clin Oncol 1994; 12:1748-53.
12. Trimble E L, Adams J D, Vena D, Hawkins M J, Friedman M A, Fisherman J S, et al. Paclitaxel for platinum-refractory ovarian cancer. Results from the first 1000 patients registered to National Cancer Institute Treatment Referral Centre 9103. J Clin Oncol 1993; 11:2405-10.
13. Weiss R, Donehower R C, Wierwick P H, Ohnuma T, Gralla R J, Trump D L, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263-8.
14. Gore M E, Levy V, Rustin G, Perren T, Calvert A H, Earl H, et al. Paclitaxel Taxol® in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72:1016-9.
15. Schiller J H, Storer B, Tutsch K, Arzoomanian R, Albert D, Feierabend C, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12:241-8.
16. Rowinsky E K, Chaudhry V, Cornblath D R, Donehower R C. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993; 15:107-15.